BioCentury | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

...uveitis program after reproxalap (ADX-102) missed the primary and secondary endpoints in the Phase III SOLACE...
BioCentury | Aug 23, 2018
Politics & Policy

U.K. unveils contingency plans for no-deal Brexit scenario

...continued funding for U.K. organizations that received awards from competitive bids (see "U.K. Offers No Solace...
BioCentury | Aug 16, 2018
Politics & Policy

U.K. offers no solace on future access to EU research funding

The U.K. government reiterated a promise that Brexit will not affect funding of current U.K. projects under Horizon 2020, the European Commission's research funding program, but stopped short of clarifying U.K. researchers' access to Horizon...
BioCentury | Nov 21, 2011
Product Development

Not depressed yet

...on Hamilton Depression Rating Scale (HDRS) units). Win some, lose some TC-5214's partners might take solace...
BioCentury | Aug 22, 2011
Company News

Creabilis management update

...Hired: Alex Leech as VP, head of finance and operations, formerly head of operations at Solace Pharmaceuticals Inc....
BioCentury | Oct 4, 2010
Company News

Creabilis management update

...Luxembourg, Luxembourg Business: Inflammation, Autoimmune, Dermatology Hired: Eliot Forster as CEO, formerly CEO of Solace Pharmaceuticals Inc....
BioCentury | Sep 30, 2010
Company News

Forster joining Creabilis as CEO

...company Creabilis S.A. (Luxembourg, Luxembourg) hired Eliot Forster as CEO. Previously, Forster was CEO of Solace Pharmaceuticals Inc....
BioCentury | Apr 22, 2010
Targets & Mechanisms

Promoting pain resolution

...to show the role of resolvins in treating inflammatory pain," said Alasdair Naylor, CSO of Solace Pharmaceuticals Inc....
...happens in humans than have animal models of neuropathic pain, said Solace CEO Eliot Forster. Solace...
...Lake Forest, Ill. Javelin Pharmaceuticals Inc. (NYSE-A:JAV), Cambridge, Mass. Resolvyx Pharmaceuticals Inc. , Bedford, Mass. Solace Pharmaceuticals Inc....
BioCentury | Jan 19, 2009
Clinical News

SLC022: Phase IIa started

...in 204 patients to compare 300 mg of oral SLC022 given 3-times daily with placebo. Solace Pharmaceuticals Inc....
BioCentury | Dec 18, 2008
Cover Story

Uncoupling pain from the psyche

...will likely be used in a combinatorial setting," said Woolf, who is a cofounder of Solace Pharmaceuticals Inc....
...multi-pronged approach may be advantageous for therapy of chronic pain syndromes," he told SciBX . Solace...
...A/S (CSE:NEUR), Ballerup, Denmark Neurotune AG , Schlieren-Zurich, Switzerland NoNO Inc. , Toronto, Ontario, Canada Solace Pharmaceuticals Inc....
Items per page:
1 - 10 of 24
BioCentury | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

...uveitis program after reproxalap (ADX-102) missed the primary and secondary endpoints in the Phase III SOLACE...
BioCentury | Aug 23, 2018
Politics & Policy

U.K. unveils contingency plans for no-deal Brexit scenario

...continued funding for U.K. organizations that received awards from competitive bids (see "U.K. Offers No Solace...
BioCentury | Aug 16, 2018
Politics & Policy

U.K. offers no solace on future access to EU research funding

The U.K. government reiterated a promise that Brexit will not affect funding of current U.K. projects under Horizon 2020, the European Commission's research funding program, but stopped short of clarifying U.K. researchers' access to Horizon...
BioCentury | Nov 21, 2011
Product Development

Not depressed yet

...on Hamilton Depression Rating Scale (HDRS) units). Win some, lose some TC-5214's partners might take solace...
BioCentury | Aug 22, 2011
Company News

Creabilis management update

...Hired: Alex Leech as VP, head of finance and operations, formerly head of operations at Solace Pharmaceuticals Inc....
BioCentury | Oct 4, 2010
Company News

Creabilis management update

...Luxembourg, Luxembourg Business: Inflammation, Autoimmune, Dermatology Hired: Eliot Forster as CEO, formerly CEO of Solace Pharmaceuticals Inc....
BioCentury | Sep 30, 2010
Company News

Forster joining Creabilis as CEO

...company Creabilis S.A. (Luxembourg, Luxembourg) hired Eliot Forster as CEO. Previously, Forster was CEO of Solace Pharmaceuticals Inc....
BioCentury | Apr 22, 2010
Targets & Mechanisms

Promoting pain resolution

...to show the role of resolvins in treating inflammatory pain," said Alasdair Naylor, CSO of Solace Pharmaceuticals Inc....
...happens in humans than have animal models of neuropathic pain, said Solace CEO Eliot Forster. Solace...
...Lake Forest, Ill. Javelin Pharmaceuticals Inc. (NYSE-A:JAV), Cambridge, Mass. Resolvyx Pharmaceuticals Inc. , Bedford, Mass. Solace Pharmaceuticals Inc....
BioCentury | Jan 19, 2009
Clinical News

SLC022: Phase IIa started

...in 204 patients to compare 300 mg of oral SLC022 given 3-times daily with placebo. Solace Pharmaceuticals Inc....
BioCentury | Dec 18, 2008
Cover Story

Uncoupling pain from the psyche

...will likely be used in a combinatorial setting," said Woolf, who is a cofounder of Solace Pharmaceuticals Inc....
...multi-pronged approach may be advantageous for therapy of chronic pain syndromes," he told SciBX . Solace...
...A/S (CSE:NEUR), Ballerup, Denmark Neurotune AG , Schlieren-Zurich, Switzerland NoNO Inc. , Toronto, Ontario, Canada Solace Pharmaceuticals Inc....
Items per page:
1 - 10 of 24